Homestead Advisers Corp Acquires 36,700 Shares of Envista Holdings Co. (NYSE:NVST)

Homestead Advisers Corp lifted its stake in shares of Envista Holdings Co. (NYSE:NVST - Free Report) by 20.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 218,300 shares of the company's stock after purchasing an additional 36,700 shares during the quarter. Homestead Advisers Corp owned 0.13% of Envista worth $4,211,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Venturi Wealth Management LLC grew its stake in shares of Envista by 528.4% in the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock valued at $38,000 after buying an additional 1,638 shares during the period. GAMMA Investing LLC grew its stake in Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock valued at $44,000 after purchasing an additional 538 shares during the period. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Envista in the fourth quarter worth about $53,000. Mitsubishi UFJ Trust & Banking Corp purchased a new position in shares of Envista during the 4th quarter valued at $86,000. Finally, KBC Group NV grew its holdings in shares of Envista by 63.9% during the fourth quarter. KBC Group NV now owns 7,903 shares of the company's stock worth $152,000 after purchasing an additional 3,082 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on NVST shares. Jefferies Financial Group boosted their target price on Envista from $20.00 to $22.00 and gave the stock a "hold" rating in a research report on Thursday, January 23rd. Wells Fargo & Company set a $19.00 price target on Envista in a report on Saturday, March 8th. Mizuho assumed coverage on shares of Envista in a research report on Wednesday, December 4th. They set an "underperform" rating and a $20.00 price target on the stock. Morgan Stanley dropped their price target on Envista from $20.00 to $19.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 6th. Finally, Piper Sandler boosted their target price on shares of Envista from $17.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, February 3rd. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $20.18.

Remove Ads

Envista Stock Performance

Shares of NVST stock traded up $0.17 during trading hours on Monday, reaching $17.14. The company had a trading volume of 1,138,516 shares, compared to its average volume of 2,416,434. The firm has a market cap of $2.95 billion, a PE ratio of -2.64, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33. Envista Holdings Co. has a one year low of $15.15 and a one year high of $23.00. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. The business has a fifty day moving average price of $19.59 and a 200-day moving average price of $19.61.

Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Sell-side analysts predict that Envista Holdings Co. will post 1 earnings per share for the current fiscal year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.